Assignee
AGENUS INC
US·49 granted patents·41 pending applications·169 citations·filing 2013–2025
Top patents by PatentIndex Score
90 records- 0197US10912831B1Anti-CTLA-4 antibodies and methods of use thereofAGENUS INC·Filed 2020·Granted Feb 9, 2021·6 cites·26 claims
- 0297US10836830B2Antibodies and methods of use thereofAGENUS INC·Filed 2020·Granted Nov 17, 2020·12 cites·45 claims
- 0396US11638755B2Anti-CTLA-4 antibodies and methods of use thereofAGENUS INC·Filed 2020·Granted May 2, 2023·4 cites·20 claims
- 0496US10639368B2Anti-TIM-3 antibodies and methods of use thereofAGENUS INC·Filed 2017·Granted May 5, 2020·15 cites·32 claims
- 0596US10626181B2Nucleic acids encoding anti-OX40 antibodiesAGENUS INC·Filed 2019·Granted Apr 21, 2020·7 cites·35 claims
- 0696US10280226B2Anti-GITR antibodies and methods of use thereofAGENUS INC·Filed 2018·Granted May 7, 2019·17 cites·30 claims
- 0796US10155818B2Anti-GITR antibodies and methods of use thereofAGENUS INC·Filed 2015·Granted Dec 18, 2018·17 cites·4 claims
- 0895US10912828B2Anti-TIM-3 antibodies and methods of use thereofAGENUS INC·Filed 2020·Granted Feb 9, 2021·4 cites·36 claims
- 0995US10259882B2Anti-OX40 antibodiesAGENUS INC·Filed 2016·Granted Apr 16, 2019·16 cites·47 claims
- 1094US11242385B2Anti-CD137 antibodies and methods of use thereofAGENUS INC·Filed 2018·Granted Feb 8, 2022·8 cites·24 claims
- 1194US10144779B2Anti-CTLA-4 antibodies and methods of use thereofAGENUS INC·Filed 2016·Granted Dec 4, 2018·12 cites·92 claims
- 1293US11013802B2Anti-CTLA-4 antibodies and methods of use thereofAGENUS INC·Filed 2017·Granted May 25, 2021·5 cites·21 claims
- 1392US11267889B2Anti-CTLA-4 antibodies and methods of use thereofAGENUS INC·Filed 2020·Granted Mar 8, 2022·2 cites·26 claims
- 1492US10882908B2Anti-LAG-3 antibodies and methods of use thereofAGENUS INC·Filed 2020·Granted Jan 5, 2021·2 cites·36 claims
- 1592US10479833B2Anti-CTLA-4 antibodies and methods of use thereofAGENUS INC·Filed 2018·Granted Nov 19, 2019·8 cites·34 claims
- 1689US11345755B2Anti-PD-1 antibodies and methods of use thereofAGENUS INC·Filed 2020·Granted May 31, 2022·2 cites·25 claims
- 1789US10844119B2Anti-LAG-3 antibodies and methods of use thereofAGENUS INC·Filed 2017·Granted Nov 24, 2020·3 cites·32 claims
- 1888US10800849B2Anti-GITR antibodies and methods of use thereofAGENUS INC·Filed 2018·Granted Oct 13, 2020·2 cites·26 claims
- 1988US2025206818A1Anti-lag-3 antibodies and methods of use thereofAGENUS INC·Filed 2024·Application pending·0 cites
- 2087US10577426B2Anti-GITR antibodies and methods of use thereofAGENUS INC·Filed 2018·Granted Mar 3, 2020·3 cites·21 claims
- 2186US10323091B2Anti-PD-1 antibodies and methods of use thereofAGENUS INC·Filed 2016·Granted Jun 18, 2019·5 cites·94 claims
- 2285US12246066B2Anti-CTLA-4 antibodies and methods of use thereofAGENUS INC·Filed 2023·Granted Mar 11, 2025·0 cites·19 claims
- 2385US11692042B2Anti-CD73 antibodies and methods of use thereofAGENUS INC·Filed 2019·Granted Jul 4, 2023·3 cites·22 claims
- 2485US11472883B2Methods of administering anti-OX40 antibodiesAGENUS INC·Filed 2020·Granted Oct 18, 2022·1 cites·15 claims
- 2585US11332536B2Vectors comprising nucleic acids encoding anti-OX40 antibodiesAGENUS INC·Filed 2020·Granted May 17, 2022·1 cites·22 claims
- 2684US11993653B2Antibodies and methods of use thereofAGENUS INC·Filed 2019·Granted May 28, 2024·2 cites·19 claims
- 2784US11447557B2Antibodies and methods of use thereofAGENUS INC·Filed 2016·Granted Sep 20, 2022·3 cites·46 claims
- 2884US11136404B2Anti-OX40 antibodiesAGENUS INC·Filed 2019·Granted Oct 5, 2021·1 cites·64 claims
- 2984US10829559B2Anti-GITR antibodies and methods of use thereofAGENUS INC·Filed 2019·Granted Nov 10, 2020·1 cites·8 claims
- 3084US2023167186A1Methods of administering anti-ox40 antibodiesAGENUS INC·Filed 2022·Application pending·0 cites
- 3184US2023108348A1Methods of administering anti-ox40 antibodiesAGENUS INC·Filed 2022·Application pending·0 cites
- 3283US11021537B2Anti-TIGIT antibodies and methods of use thereofAGENUS INC·Filed 2018·Granted Jun 1, 2021·2 cites·70 claims
- 3382US2023039577A1Anti-gitr antibodies and methods of use thereofAGENUS INC·Filed 2022·Application pending·0 cites
- 3482US2024181048A1Anti-tim-3 antibodies and methods of use thereofAGENUS INC·Filed 2023·Application pending·0 cites
- 3581US11065317B2Heat shock protein-binding peptide compositions and methods of use thereofAGENUS INC·Filed 2019·Granted Jul 20, 2021·1 cites·43 claims
- 3680US11359028B2Anti-OX40 antibodies and anti-GITR antibodiesAGENUS INC·Filed 2019·Granted Jun 14, 2022·1 cites·16 claims
- 3780US2023406946A1Antibodies and methods of use thereofAGENUS INC·Filed 2022·Application pending·0 cites
- 3880US2023399413A1Antibodies and methods of use thereofAGENUS INC·Filed 2022·Application pending·0 cites
- 3979US12492257B2Anti-CTLA-4 antibodies and methods of use thereofAGENUS INC·Filed 2022·Granted Dec 9, 2025·0 cites·20 claims
- 4079US11680098B2Antibodies that specifically bind human CD96AGENUS INC·Filed 2020·Granted Jun 20, 2023·1 cites·22 claims
- 4179US2022098316A1Anti-ox40 antibodies and methods of use thereofAGENUS INC·Filed 2021·Application pending·0 cites
- 4278US12492393B2Anti-CD137 antibodies and methods of use thereofAGENUS INC·Filed 2021·Granted Dec 9, 2025·0 cites·28 claims
- 4378US2024141047A1Anti-tigit antibodies and methods of use thereofAGENUS INC·Filed 2023·Application pending·0 cites
- 4476US2022372149A1Anti-pd-1 antibodies and methods of use thereofAGENUS INC·Filed 2022·Application pending·0 cites
- 4575US12187795B2Anti-LAG-3 antibodies and methods of use thereofAGENUS INC·Filed 2020·Granted Jan 7, 2025·0 cites·18 claims
- 4675US12011481B2Anti-TIM-3 antibodies and methods of use thereofAGENUS INC·Filed 2021·Granted Jun 18, 2024·0 cites·28 claims
- 4775US11897962B2Anti-GITR antibodies and methods of use thereofAGENUS INC·Filed 2020·Granted Feb 13, 2024·0 cites·11 claims
- 4875US2025360209A1Anti-ctla-4 antibodies and methods of use thereofAGENUS INC·Filed 2025·Application pending·0 cites
- 4974US11993651B2Anti-lag-3 antibodies and methods of use thereofAGENUS INC·Filed 2020·Granted May 28, 2024·0 cites·15 claims
- 5074US11098117B2Anti-CD137 antibodies and methods of use thereofAGENUS INC·Filed 2020·Granted Aug 24, 2021·0 cites·25 claims
Showing the top 50 of 90 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →